ALNYLAM PHARMACEUTICALS, INC. 10-Q filing
Filed 2025-07-31 · Report date 2025-06-30 · 2025
Filing metadata
- Accession number
- 0001178670-25-000090
- Form type
- 10-Q
- CIK
- 0001178670
- Primary document
- https://www.sec.gov/Archives/edgar/data/1178670/000117867025000090/alny-20250630.htm
Extracted primary information
This filing includes deterministic financial metrics extracted from public filing data for ALNYLAM PHARMACEUTICALS, INC..
Reported financial metrics
| Metric | Current | Prior | Change |
|---|---|---|---|
| Revenue | $1.4B | - | - |
| Cost Of Revenue | $212.2M | - | - |
| Operating Income | $1.9M | - | - |
| Net Income | $-123.8M | - | - |
| Eps Basic | -0.95 | - | - |
| Eps Diluted | -0.95 | - | - |
| Cash And Equivalents | $1.1B | - | - |
| Total Assets | $4.6B | - | - |
| Total Liabilities | $4.3B | - | - |
| Shareholders Equity | $250.6M | - | - |
| Operating Cash Flow | $35.4M | - | - |
| Capital Expenditures | $23.3M | - | - |